Castle Biosciences (CSTL) EBT (2018 - 2026)

Castle Biosciences has reported EBT for 9 years, with the latest figure at -$1.7 million in Q2 2026.

• Quarterly EBT fell 1081.82% year-over-year to -$1.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$19.2 million (down 87.4% YoY) and the FY2025 annual result came in at -$29.5 million, down 236.87% from the prior year.
• EBT grew to -$1.7 million in Q2 2026 per CSTL's latest filing, from -$14.4 million in the prior quarter.
• Over five years, EBT peaked at $8.3 million in Q3 2024 and troughed at -$29.2 million in Q1 2023.
• A 5-year average of -$8.4 million and a median of -$3.2 million in 2022 frame the typical range for EBT.
• The sharpest annual moves came in 2024 and 2026: EBT surged 410.31% in 2024, then tumbled 1081.82% in 2026.
• Over 5 years, EBT stood at -$20.6 million in 2022, then jumped by 87.64% to -$2.5 million in 2023, then soared by 410.31% to $7.9 million in 2024, then slumped by 134.42% to -$2.7 million in 2025, then surged by 37.73% to -$1.7 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$1.7 million, -$14.4 million, and -$2.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.